How fast will I lose weight on GLP-1s and is it sustainable?

Short answer

• Many people lose noticeable weight within weeks and substantial weight over months, but speed and amount vary a lot by drug, dose, and person.
• Semaglutide (Wegovy) and tirzepatide (Zepbound/Mounjaro) produce the largest average losses in trials; liraglutide (Saxenda) less so.
• Weight is often regained if the medicine is stopped unless you build lasting lifestyle and behavioral changes, so long‑term treatment is commonly needed to sustain maximum benefit.

What to expect (typical clinical-trial results and timelines)

• First 1–3 months: appetite drops, many people lose a few kilograms (a few lbs/wk can occur early). Dose escalation schedules also slow early speed.
• 3–6 months: most of the early weight loss occurs in this window. Typical ranges by drug (trial averages):
  • Tirzepatide (Zepbound for weight loss; Mounjaro for diabetes): often the largest losses—many trials show mean losses of ~15–20% body weight at ~9–12 months on the higher doses.
  • Semaglutide 2.4 mg (Wegovy): roughly 10–15% mean weight loss at ~12–18 months in STEP trials (about 15% at 68 weeks).
  • Liraglutide 3.0 mg (Saxenda): smaller effect, roughly 5–10% at ~1 year in trials.
• 6–12 months: the rate slows and weight often plateaus. Further small losses are possible but slower.
• If you stop the drug: many people regain a large portion of the lost weight within months to a year unless other strategies are firmly in place.

Concrete example

• If you weigh 100 kg (220 lb): a 10% loss = 10 kg (22 lb); on Wegovy many people average ~10–15 kg (22–33 lb) after about a year; on higher-dose tirzepatide some people average more (15–20+ kg), while on Saxenda the average is lower (~5–10 kg).

Is it sustainable?

• Medication + behavior change is the best path to lasting weight loss. GLP-1s change appetite and food reward, which helps create the calorie deficit—but unless the underlying habits, food environment, activity, and coping strategies change, stopping medication usually leads to regain.
• Many clinicians therefore treat obesity as a chronic condition: ongoing medication may be recommended long-term for maintenance, similar to how we treat hypertension or diabetes.

Risks, practical issues, and things to discuss with your clinician

• Side effects: nausea, vomiting, diarrhea, constipation, gallbladder issues, and rare but serious risks (pancreatitis, thyroid C‑cell tumors in animals). Not appropriate if pregnant or trying to conceive.
• Cost and access: insurance coverage varies (Wegovy/Zepbound may be covered inconsistently); some drugs are costly if uninsured.
• Need for medical supervision: dose escalation, safety checks, and attention to vitamins/nutrition and other meds are important.

Recommended brands and services (and why)

• Wegovy (semaglutide 2.4 mg) — FDA‑approved specifically for chronic weight management; strong trial evidence (STEP) for ~10–15% average loss.
• Zepbound (tirzepatide) — newer FDA‑approved option for weight loss with very strong results in trials (often greater average percent loss than semaglutide). If not available, Mounjaro (tirzepatide) is used for diabetes and sometimes prescribed off‑label for weight loss under supervision.
• Saxenda (liraglutide) — older GLP‑1 option with more modest weight loss; may be an option if others aren’t suitable.
• Telemedicine weight‑management services (examples): Ro (offers supervised GLP‑1 programs and remote follow‑up), PlushCare (telehealth primary care + weight management), and local obesity or bariatric clinics for comprehensive in‑person care. These services can make access and monitoring easier but check licensure, protocols, and costs.
• For specialist care: find an obesity medicine physician through the Obesity Medicine Association’s "Find a Specialist" tool or seek a multidisciplinary bariatric/metabolic clinic (e.g., large academic centers like Cleveland Clinic Bariatric & Metabolic Institute) if you want coordinated medical, nutrition, and behavioral support.

Practical tips to improve outcome and sustainability

• Combine medication with structured nutrition counseling (RD), behavioral therapy or coaching, and an exercise plan.
• Expect dose escalation: most schedules ramp slowly to reduce GI side effects.
• Track progress and side effects, and plan for long‑term maintenance (including the possibility of continuing medication).
• Discuss birth control/planning if applicable and avoid pregnancy while taking GLP‑1s.

Next steps

• Talk with your primary care doctor or an obesity medicine specialist to see which drug (if any) fits your health profile, insurance, and goals. If you want names of local specialists or telemedicine programs that serve your state, tell me your state (or ZIP) and I can list options.